Key Points
- CEO Patrick Miles sold 100,000 shares on Jan. 5 at an average price of $21.01 for $2.101M, lowering his stake to 5,135,398 shares (a 1.91% reduction); he also sold 100k shares on Dec. 1 and 100k on Nov. 3, bringing recent insider sales to 300,000 shares.
- Alphatec reported an earnings beat on Oct. 30 with EPS of $0.03 (vs. -$0.06 expected) and revenue of $196.5M, up 30.4% year-over-year, though analysts still forecast a full-year EPS of around -1.08.
- The stock trades near $21.79 with a market cap of about $3.24B and a 12-month high of $22.66, and analyst coverage is generally positive with a consensus "Moderate Buy" and an average price target of roughly $22.45.
Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) CEO Patrick Miles sold 100,000 shares of the business's stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $21.01, for a total value of $2,101,000.00. Following the completion of the sale, the chief executive officer directly owned 5,135,398 shares of the company's stock, valued at approximately $107,894,711.98. This represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Patrick Miles also recently made the following trade(s):
- On Monday, December 1st, Patrick Miles sold 100,000 shares of Alphatec stock. The stock was sold at an average price of $22.11, for a total value of $2,211,000.00.
- On Monday, November 3rd, Patrick Miles sold 100,000 shares of Alphatec stock. The shares were sold at an average price of $18.96, for a total value of $1,896,000.00.
Alphatec Stock Performance
Shares of ATEC opened at $21.79 on Wednesday. The stock has a market capitalization of $3.24 billion, a PE ratio of -20.95 and a beta of 1.01. The business's fifty day moving average price is $20.43 and its 200 day moving average price is $16.18. The company has a debt-to-equity ratio of 43.02, a current ratio of 1.99 and a quick ratio of 1.24. Alphatec Holdings, Inc. has a 12-month low of $8.81 and a 12-month high of $22.66.
Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. During the same period last year, the company posted ($0.28) earnings per share. The firm's revenue for the quarter was up 30.4% on a year-over-year basis. Equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.
Wall Street Analysts Forecast Growth
ATEC has been the subject of several recent research reports. Loop Capital set a $25.00 target price on Alphatec in a report on Wednesday, December 10th. JPMorgan Chase & Co. assumed coverage on Alphatec in a research note on Friday, October 24th. They set an "overweight" rating and a $19.00 price objective for the company. Stifel Nicolaus assumed coverage on Alphatec in a research report on Tuesday, October 28th. They issued a "buy" rating and a $20.00 target price on the stock. Barclays boosted their price target on shares of Alphatec from $22.00 to $23.00 and gave the company an "overweight" rating in a report on Monday, November 3rd. Finally, Wall Street Zen upgraded shares of Alphatec from a "hold" rating to a "buy" rating in a research report on Saturday. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Alphatec has a consensus rating of "Moderate Buy" and an average price target of $22.45.
Check Out Our Latest Stock Analysis on ATEC
Institutional Trading of Alphatec
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Creative Planning boosted its stake in Alphatec by 0.9% during the third quarter. Creative Planning now owns 58,654 shares of the medical technology company's stock valued at $853,000 after buying an additional 534 shares in the last quarter. Valeo Financial Advisors LLC grew its stake in shares of Alphatec by 2.1% in the 3rd quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company's stock worth $600,000 after purchasing an additional 846 shares during the last quarter. Norden Group LLC raised its holdings in shares of Alphatec by 2.6% in the 3rd quarter. Norden Group LLC now owns 36,676 shares of the medical technology company's stock worth $533,000 after purchasing an additional 939 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Alphatec by 2.8% in the 3rd quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company's stock worth $503,000 after purchasing an additional 949 shares in the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in Alphatec by 8.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company's stock worth $131,000 after buying an additional 955 shares in the last quarter. Institutional investors own 66.35% of the company's stock.
About Alphatec
(
Get Free Report)
Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.
Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
